ArticleInternational journal of hematology2019

Binimetinib, a novel MEK1/2 inhibitor, exerts anti-leukemic effects under inactive status of PI3Kinase/Akt pathway.

Kanae Sakakibara et al.PubMed ↗Publisher ↗

No numbers read from the abstract.